Brief: Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025 - SEC Filing
11/06/2025 12:52
June 11 (Reuters) - Tempest Therapeutics Inc TPST.O: TEMPEST THERAPEUTICS INC - TERMINATES ATM PROSPECTUS SUPPLEMENT DATED FEBRUARY 6, 2025 - SEC FILING Source text: [ID:n0001193125-25-138802] Further company coverage: TPST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T